Anxieties about the quality of generic drugs are one of reasons why these drugs are not generally used in therapies in Japan. To reduce anxieties, we propose a statistical and objective method to evaluate the quality of generic drugs using the coefficient of variances (CVs) calculated from their pharmacokinetic parameters. CVs were estimated from AUC, Cmax, Tmax, t1/2, and MRT, which were provided as publicly-available drug information. The generic drug assessment tool (G-DAT), an original equation derived from the ratio of CVs of corresponding generic to original drugs, and the quality of generic drugs was statistically evaluated. As expected, when evaluated with G-DAT, there was little variance between original and generic drugs using 11 medicines. Antihypertensive dihydropyridines with a lower solubility were shown to have a larger CV. No significant difference in CVs was observed when famotidine and ebastine OD tablets were taken with or without water. G-DAT and the ratio of CVs (CCVs) of generic to original drugs revealed pharmacokinetic equivalences between generic and original drugs. The proposed comparative evaluation showing equivalent pharmacokinetics of generic to original drugs can be used as one solution to reduce anxieties and increase the reliability of generic drugs.
Introduction
The cost of medical care in Japan keeps increasing year after year due to rapid aging of the population resulting from a decline in the birthrate. A major policy change for maintaining the health-insurance system that covers all of its citizens has been taken in order to cut down the cost.
1) The Ministry of Health, Labour, and Welfare in Japan has implemented multilateral policies for medical treatment fees. To reduce costs, a preferential policy for the increased use of generic drugs, which have a lower usage in Japan than Europe and the United States, is being car- As the quality of generic drugs keeps improving, the prescription of generic drugs has been promoted. Drug safety and bioequivalence studies for healthy adults were problems that needed to be addressed on the application for approval of the production of generic drugs before 1997.
Guidelines on the bioequivalence study of generic drugs were formulated by the former Ministry of Health, and Welfare in 1997. In these guidelines, a dissolution test was added to the revised bioequivalence study. All generic drugs, which were put on the market before and after 1997, underwent a re-evaluation of drug quality according to these revised guidelines. The results of the study were reported in the orange book, a data book of drug information used therapeutically in Japan. 2) Previously, generic drugs had not been used in therapy, however policy changes for the use of these drugs were promoted. The reasons why generic drugs were not generally used were anxieties about the quality of the drugs, lack of drug information, and an unsteady supply of the drugs.
These reasons have not been overcome completely and physicians may not fully understand the processes on approval of generic drugs and test contents in the orange book. The lack of reliability of the therapeutic effects of generic drugs, depending on the quality, caused physicians to hesitate in using these drugs. 3) Since the patents of some oral medicines in therapeutic use expired after 2010, the generic drugs of these off-patent medicines will be produced and put on the market in the near future. This may possibly result in increased opportunities for the use of these generic drugs. Therefore, it is necessary to reduce anxieties about the quality of generic drugs in order to increase opportunities for their prescription.
We strive torwards a statistical and objective method to evaluate the quality of generic drugs in order to reduce anxieties and increase the use of these drugs. In this study, we propose an analyti- 
Methods

Pharmacokinetic parameters
Pharmacokinetic parameters, AUC, Cmax, 
Evaluations for the variance of the quality between original and generic drug
Analysis of the correlation between solubility and CV
Pharmacokinetic parameters obtained by the administration of more than two tablets in the bioequivalence study were excluded from analysis because variances may become larger. The parameters represented as the standard error were also avoided. The parameters from an unmetabolite were adopted even if active metabolites were observed since pharmaceutical vendors rarely provide the pharmacokinetic parameters of metabolites.
Results
Comparison of generic drugs by G-DAT
G-DATs of amlodipine besylate 5 mg tablets marketed by thirty-three pharmaceutical vendors are listed in Table 1 . Thirty-three G-DATs did One product each was observed to have more than 
CVs affected by water solubility of generic drugs
The CVs of AUC and Cmax for loxoprofen sodium hydrate and manidipine hydrochloride, which are water soluble and practically insoluble, respectively, are shown in Table 2 . The CVs of AUC and Cmax for manidipine were significantly higher than those for loxoprofen.
To further investigate the correlation between solubility and CV, antihypertensive dihydropyridines, as multiproducts, were analyzed ( Table 3) .
Although these compounds have a common skel- were significantly higher than those for levofloxacin, as shown in Table 4 .
CVs for orally-disintegrating tablets taken with or without water
The kinetic parameters of orally-disintegrating tablets (ODTs), taken with or without water, were investigated in the bioequivalent study. CVs of AUC and Cmax for ODTs of famotidine and Dissolution test was performed according to the method described in the Japanese Pharmacopoeia, Fifteenth Edition.
Fig. 4 Dissolution curves of itraconazole tablets
Dissolution test was performed according to the method described in the Japanese Pharmacopoeia, Fifteenth Edition.
ebastine tablets were estimated with the available data ( Table 5 ). If ODTs are taken without water, poor dissolution of the tablets is more likely to occur, and resulting in fluctuating absorption of the drugs. Therefore, it was speculated that CVs without water were larger than those with water.
However, significant differences in CVs of ODTs taken with or without water were not observed.
This suggests the equivalence of the therapeutic effect of these ODTs, even if taken them with or without water. These ODTs are effective for patients with restricted water intake, or when water is unavailable, although ODTs should be taken with water.
Evaluation of generic drugs
The In this case, it has been suggested that the thera- In this report, the quality variance of most generic drugs was evaluated to be little and in a de- fined area in the frequency distribution for G-DATs ( Figs. 1 and 2) . The correlation between solubility and CV were analyzed with antihypertensive dihydropyridines ( Table 3) These improvements seem to achieve lower CVs and result in stabilization of CCVs. Therefore, our proposed evaluation method using G-DAT and CCVs shown in Fig. 4 can be a useful tool for judging whether generic class II drugs are adequately formulated to improve solubility and rate of dissolution.
Our method for evaluating the quality of generic drugs proposed in this report can be applied to drugs not only in Japan but also in other countries if pharmacokinetic parameters of the drugs are available.
